blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2825649

EP2825649 - SELECTIVE CELL TARGETING USING ADENOVIRUS AND CHEMICAL DIMERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.07.2020
Database last updated on 09.04.2026
FormerThe patent has been granted
Status updated on  28.06.2019
FormerGrant of patent is intended
Status updated on  07.03.2019
FormerExamination is in progress
Status updated on  28.04.2017
Most recent event   Tooltip08.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 10.08.2022  [2022/32]
Applicant(s)For all designated states
The Salk Institute for Biological Studies
Office of Technology Management 10010 N. Torrey Pines Road
La Jolla, CA 92037 / US
[2015/04]
Inventor(s)01 / O'SHEA, Clodagh
5052 Long Branch Ave.
San Diego, California 92107 / US
02 / MIYAKE-STONER, Shigeki
3951 H Miramar St.
La Jolla, California 92037 / US
03 / POWERS, Colin
11595 Caminito La Bar 12
San Diego, California 92126 / US
 [2015/04]
Representative(s)Docherty, Robert Charles, et al
Symbiosis IP Limited
York Biotech Campus
Office 14FA05
Sand Hutton
York, YO41 1LZ / GB
[N/P]
Former [2019/31]Docherty, Robert Charles, et al
Symbiosis IP Limited
NAFIC
Office 14FA05
Sand Hutton
York, North Yorkshire YO41 1LZ / GB
Former [2015/04]Docherty, Robert Charles, et al
Symbiosis IP Limited
106 Heworth Green
York YO31 7TQ / GB
Application number, filing date13760608.313.03.2013
[2019/31]
WO2013US31002
Priority number, dateUS201261610416P13.03.2012         Original published format: US 201261610416 P
[2015/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2013138505
Date:19.09.2013
Language:EN
[2013/38]
Type: A1 Application with search report 
No.:EP2825649
Date:21.01.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 19.09.2013 takes the place of the publication of the European patent application.
[2015/04]
Type: B1 Patent specification 
No.:EP2825649
Date:31.07.2019
Language:EN
[2019/31]
Search report(s)International search report - published on:KR19.09.2013
(Supplementary) European search report - dispatched on:EP11.01.2016
ClassificationIPC:C12N15/861, A61K35/761
[2016/06]
CPC:
A61K35/761 (EP,US); A61K48/00 (US); A61P35/00 (EP);
A61P43/00 (EP); C12N15/113 (US); C12N15/86 (EP,US);
C12N7/00 (US); C07K2319/20 (EP,US); C12N2710/10034 (US);
C12N2710/10052 (US); C12N2710/10345 (EP,US) (-)
Former IPC [2015/04]C12N15/62, C12N15/34, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/04]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:SELEKTIVES TARGETING VON ZELLEN MITTELS ADENOVIRALER UND CHEMISCHER DIMERE[2015/04]
English:SELECTIVE CELL TARGETING USING ADENOVIRUS AND CHEMICAL DIMERS[2015/04]
French:CIBLAGE CELLULAIRE SÉLECTIF À L'AIDE D'ADÉNOVIRUS ET DE DIMÈRES CHIMIQUES[2015/04]
Entry into regional phase25.09.2014National basic fee paid 
25.09.2014Search fee paid 
25.09.2014Designation fee(s) paid 
25.09.2014Examination fee paid 
Examination procedure25.09.2014Examination requested  [2015/04]
25.07.2016Amendment by applicant (claims and/or description)
02.05.2017Despatch of a communication from the examining division (Time limit: M04)
30.08.2017Reply to a communication from the examining division
30.07.2018Despatch of a communication from the examining division (Time limit: M04)
14.11.2018Reply to a communication from the examining division
06.12.2018Despatch of a communication from the examining division (Time limit: M01)
19.12.2018Reply to a communication from the examining division
08.03.2019Communication of intention to grant the patent
18.06.2019Fee for grant paid
18.06.2019Fee for publishing/printing paid
18.06.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  02.05.2017
Opposition(s)03.06.2020No opposition filed within time limit [2020/33]
Fees paidRenewal fee
25.03.2015Renewal fee patent year 03
10.03.2016Renewal fee patent year 04
10.03.2017Renewal fee patent year 05
13.03.2018Renewal fee patent year 06
13.03.2019Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.03.2013
AL31.07.2019
CY31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
MC31.07.2019
MK31.07.2019
MT31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SI31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
LU13.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
[2022/32]
Former [2022/27]HU13.03.2013
AL31.07.2019
CY31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
MC31.07.2019
MT31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SI31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
LU13.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/12]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
MC31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SI31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
LU13.03.2020
BE31.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/07]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
MC31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SI31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
LU13.03.2020
CH31.03.2020
LI31.03.2020
Former [2021/04]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
MC31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SI31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
LU13.03.2020
Former [2020/49]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
MC31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SI31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
Former [2020/37]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SI31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
Former [2020/36]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
IS30.10.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
Former [2020/27]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SK31.07.2019
SM31.07.2019
TR31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
IS24.02.2020
Former [2020/25]AL31.07.2019
CZ31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
SK31.07.2019
TR31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
IS24.02.2020
Former [2020/24]AL31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
TR31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
IS24.02.2020
Former [2020/23]AL31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
IT31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
PL31.07.2019
RO31.07.2019
RS31.07.2019
SE31.07.2019
TR31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
IS30.11.2019
PT02.12.2019
Former [2020/22]AL31.07.2019
DK31.07.2019
EE31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
RS31.07.2019
SE31.07.2019
TR31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
IS30.11.2019
PT02.12.2019
Former [2020/17]AL31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
RS31.07.2019
SE31.07.2019
TR31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
IS30.11.2019
PT02.12.2019
Former [2020/15]AL31.07.2019
ES31.07.2019
FI31.07.2019
HR31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
RS31.07.2019
SE31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
IS30.11.2019
PT02.12.2019
Former [2020/12]ES31.07.2019
FI31.07.2019
HR31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
RS31.07.2019
SE31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
IS30.11.2019
PT02.12.2019
Former [2020/11]ES31.07.2019
FI31.07.2019
HR31.07.2019
LT31.07.2019
LV31.07.2019
NL31.07.2019
RS31.07.2019
SE31.07.2019
BG31.10.2019
NO31.10.2019
GR01.11.2019
PT02.12.2019
Former [2020/10]FI31.07.2019
LT31.07.2019
NL31.07.2019
SE31.07.2019
BG31.10.2019
NO31.10.2019
PT02.12.2019
Former [2020/09]FI31.07.2019
LT31.07.2019
NL31.07.2019
NO31.10.2019
Former [2020/08]LT31.07.2019
NO31.10.2019
Documents cited:Search[XYI] WO2012024350  (SALK INST FOR BIOLOGICAL STUDI et al.) [X] 1-5,7-14 * page 30, line 12 - line 28 *[Y] 6 [I] 15,16
 [Y]   JOEL N. GLASGOW ET AL: "A Strategy for Adenovirus Vector Targeting with a Secreted Single Chain Antibody", PLOS ONE, vol. 4, no. 12, 21 December 2009 (2009-12-21), pages e8355, XP055163048, DOI: 10.1371/journal.pone.0008355 [Y] 6 * abstract * * figure 1 *

DOI:   http://dx.doi.org/10.1371/journal.pone.0008355
 [AD]   WAEHLER REINHARD ET AL: "Engineering targeted viral vectors for gene therapy", NATURE REVIEWS GENETICS, vol. 8, no. 8, 1 August 2007 (2007-08-01), pages 573 - 587, XP002663591, ISSN: 1471-0056, [retrieved on 20070703], DOI: 10.1038/NRG2141 [AD] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1038/NRG2141
 [A]   CHONG HEUNG ET AL: "A system for small-molecule control of conditionally replication-competent adenoviral vectors", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, vol. 5, no. 2, 1 February 2002 (2002-02-01), pages 195 - 203, XP002344532, ISSN: 1525-0016, DOI: 10.1006/MTHE.2002.0531 [A] 1-16 * the whole document *

DOI:   http://dx.doi.org/10.1006/mthe.2002.0531
International search[X] WO2012024350  (SALK INST FOR BIOLOGICAL STUDI et al.) [X]
 [A] US6506379  (CLACKSON TIMOTHY P et al.) [A]
 [A] US6984635  (SCHREIBER STUART L et al.) [A]
 [Y]   GLASGOW, JOEL N. ET AL.: "A strategy for adenovirus vector targeting with a secreted single chain antibody", PLOS ONE, vol. 4, no. 12, 21 December 2009 (2009-12-21), pages E8355, XP055163048 [Y]

DOI:   http://dx.doi.org/10.1371/journal.pone.0008355
 [A]   VERHEIJE, M. H. ET AL.: "Retargeting of viruses to generate oncolytic agent s", ADVANCES IN VIROLOGY, vol. 2012, 14 November 2011 (2011-11-14), pages 1 - 15, XP055163052 [A]

DOI:   http://dx.doi.org/10.1155/2012/798526
by applicantWO2012024350
 US2011048006
   PESONEN, S. ET AL., MOLECULAR PHARMACEUTICS, vol. 8, no. 1, 2010, pages 12 - 28
   ZHANG H; BEREZOV A; WANG Q; ZHANG G; DREBIN J; MURALI R ET AL.: "ErbB receptors: from oncogenes to targeted cancer therapies", J CLIN INVEST, vol. 117, no. 8, 2007, pages 2051 - 2058 [A]
   LI HJ; EVERTS M; PEREBOEVA L; KOMAROVA S; IDAN A; CURIEL DT ET AL.: "Adenovirus tumor targeting and hepatic untargeting by a coxsackie/adenovirus receptor ectodomain anti-carcinoembryonic antigen bispecific adapter", CANCER RES., vol. 67, no. 11, 2007, pages 5354 - 5361
   HAISMA HJ; PINEDO HM; RIJSWIJK A; DER MEULEN-MUILEMAN I; SOSNOWSKI BA; YING W ET AL.: "Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM", GENE THER, vol. 6, no. 8, 1999, pages 1469 - 1474, XP001157238, DOI: doi:10.1038/sj.gt.3300969

DOI:   http://dx.doi.org/10.1038/sj.gt.3300969
   DE VRIJ J; UIL TG; VAN DEN HENGEL SK; CRAMER SJ; KOPPERS-LALIC D; VERWEIJ MC ET AL.: "Adenovirus targeting to HLA-A1/MAGE-A1-positive tumor cells by fusing a single-chain T-cell receptor with minor capsid protein IX", GENE THER, vol. 15, no. 13, 2008, pages 978 - 989, XP055044025, DOI: doi:10.1038/gt.2008.26

DOI:   http://dx.doi.org/10.1038/gt.2008.26
   NOUREDDINI SC; CURIEL DT: "Genetic targeting strategies for adenovirus", MOL PHARM, vol. 2, no. 5, 2005, pages 341 - 347, XP002397944, DOI: doi:10.1021/mp050045c

DOI:   http://dx.doi.org/10.1021/mp050045c
   NICKLIN SA; WU E; NEMEROW GR; BAKER AH: "The influence of adenovirus fiber structure and function on vector development for gene therapy", MOL THER, vol. 12, no. 3, 2005, pages 384 - 393, XP005472372, DOI: doi:10.1016/j.ymthe.2005.05.008

DOI:   http://dx.doi.org/10.1016/j.ymthe.2005.05.008
   BATZER ET AL., NUCLEIC ACID RES., vol. 19, 1991, pages 5081
   OHTSUKA ET AL., J. BIOL. CHEM., vol. 260, 1985, pages 2605 - 2608
   ROSSOLINI ET AL., MOL. CELL. PROBES, vol. 8, 1994, pages 91 - 98
   LEICHER ET AL., J. BIOL. CHEM., vol. 273, no. 52, 1998, pages 35095 - 35101
   MANIATIS ET AL.: "Molecular Cloning: A Laboratory Manual", 1982, COLD SPRING HARBOR LABORATORY
   SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
   NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
   PEARSON; LIPMAN, PROC. NAT'L. ACAD. SCI. USA, vol. 85, 1988, pages 2444
   "Current Protocols in Molecular Biology", 1995
   ALTSCHUL ET AL., NUC. ACIDS RES., vol. 25, 1977, pages 3389 - 3402
   ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
   HENIKOFF; HENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1989, pages 10915
   INNIS ET AL.: "PCR Protocols, A Guide to Methods and Applications", 1990, ACADEMIC PRESS, INC.
   FORD ET AL., GENE THERAPY, vol. 8, 2001, pages 1 - 4
   PROCHIANTZ, NAT. METHODS, vol. 4, 2007, pages 119 - 120
   LIEBERMAN, PHARMACEUTICAL DOSAGE FORMS, vol. 1-3, 1992
   LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999
   "Remington: The Science and Practice of Pharmacy", 2003
   PICKAR, DOSAGE CALCULATIONS, 1999
   BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19
   POZNIC, M., JBIOSCI, vol. 34, no. 2, 2009, pages 305 - 312
   TOMKO, R.P. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 94, no. 7, 2009, pages 3352 - 3356
   BERGELSON, J.M. ET AL., SCIENCE, vol. 275, no. 5304, 1997, pages 1320 - 1323
   ANDERS, M. ET AL., BR J CANCER, vol. 100, no. 2, 2009, pages 352 - 359
   DIETEL, M. ET AL., JOURNAL OF MOLECULAR MEDICINE, vol. 89, no. 6, 2011, pages 621 - 630
   MATSUMOTO, K. ET AL., UROLOGY, vol. 66, no. 2, 2005, pages 441 - 446
   REIN, D.T.; M. BREIDENBACH; D.T. CURIEL, FUTURE ONCOLOGY, vol. 2, no. 1, 2006, pages 137 - 143
   DMITRIEV, I. ET AL., J. VIROL., vol. 72, no. 12, 1998, pages 9706 - 9713
   BAUERSCHMITZ, G.J.; S.D. BARKER; A. HEMMINKI, INT J ONCOL, vol. 21, no. 6, 2002, pages 1161 - 1174
   BREIDENBACH, M. ET AL., HUM GENE THER., vol. 15, no. 5, 2004, pages 509 - 518
   CRIPE, T.P. ET AL., CANCER RES, vol. 61, no. 7, 2001, pages 2953 - 2960
   FECHNER, H. ET AL., GENE THER, vol. 7, no. 22, 2000, pages 1954 - 1968
   HEMMI, S. ET AL., HUM GENE THER, vol. 9, no. 16, 1998, pages 2363 - 2373
   HEMMINKI, A.; R.D. ALVAREZ, BIODRUGS, vol. 16, no. 2, 2002, pages 77 - 87
   KANERVA, A. ET AL., CLIN CANCER RES, vol. 8, no. 1, 2002, pages 275 - 280
   LI, Y. ET AL., CANCER RES, vol. 59, no. 2, 1999, pages 325 - 330
   MILLER, C.R. ET AL., CANCER RES, vol. 58, no. 24, 1998, pages 5738 - 5748
   REIN, D.T. ET AL., INT J CANCER, vol. 111, no. 5, 2004, pages 698 - 704
   LIU, Y.; P. VALADON; J. SCHNITZER, VIROLOGY JOURNAL, vol. 7, no. 1, 2010, pages 316
   BELOUSOVA, N. ET AL., J. VIROL., vol. 76, no. 17, 2002, pages 8621 - 8631
   BELOUSOVA, N. ET AL., J VIROL, vol. 76, no. 17, 2002, pages 8621 - 8631
   KONTERMANN, R.E., CURR OPIN MOL THER, vol. 12, no. 2, 2010, pages 176 - 183
   WAEHLER, R.; S.J. RUSSELL; D.T. CURIEL, NAT REV GENET, vol. 8, no. 8, 2007, pages 573 - 587
   CHEN, J. ET AL., PROC NATL ACAD SCI USA, vol. 92, no. 11, 1995, pages 4947 - 4951
   DE WILDT, R.M. ET AL., PROC NATL ACAD SCI USA, vol. 99, no. 13, 2002, pages 8530 - 8535
   CLACKSON, T., CHEM BIOL DRUG DES, vol. 67, no. 6, 2006, pages 440 - 442
   O'SHEA, C. ET AL., EMBO J, vol. 24, no. 6, 2005, pages 1211 - 1221
   FANG, J. ET AL., MOL THER, vol. 15, no. 6, 2007, pages 1153 - 1159
   VANEYCKEN, I. ET AL., JOURNAL OF NUCLEAR MEDICINE, vol. 51, no. 7, 2010, pages 1099 - 1106
   BEHAR, G. ET AL., FEBS JOURNAL, vol. 276, no. 14, 2009, pages 3881 - 3893
   DUFFY, M.J., CLIN CHEM, vol. 47, no. 4, 2001, pages 624 - 630
   GAINKAM, L.O. ET AL., JOURNAL OF NUCLEAR MEDICINE : OFFICIAL PUBLICATION, SOCIETY OF NUCLEAR MEDICINE, vol. 49, no. 5, 2008, pages 788 - 795
   ROOVERS, R. ET AL., CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 56, no. 3, 2007, pages 303 - 317
   HUBBARD, K.E. ET AL., GENES & DEVELOPMENT, vol. 24, no. 16, 2010, pages 1695 - 1708
   JACINTO E; HALL MN: "Tor signalling in bugs, brain and brawn", NAT REV MOL CELL BIOL, vol. 4, no. 2, 2003, pages 117 - 126
   BAYLE JH; GRIMLEY JS; STANKUNAS K; GESTWICKI JE; WANDLESS TJ; CRABTREE GR: "Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity", CHEM BIOL., vol. 13, no. 1, 2006, pages 99 - 107, XP025131705, DOI: doi:10.1016/j.chembiol.2005.10.017

DOI:   http://dx.doi.org/10.1016/j.chembiol.2005.10.017
   SONE, T. ET AL., JBIOTECHNOL., vol. 136, no. 3-4, 10 September 2008 (2008-09-10), pages 113 - 121
   SONE, T ET AL., JBIOTECHNOL, vol. 136, no. 3-4, 10 September 2008 (2008-09-10), pages 113 - 121
   KAST, P, GENE, vol. 138, 1994, pages 109 - 114
   ZHAO, L.J. ET AL., J BIOL CHEM., vol. 281, no. 48, 1 December 2006 (2006-12-01), pages 36613 - 36623
   ENGELMAN, J.A. ET AL., J CLIN INV., vol. 116, no. 10, 2 October 2006 (2006-10-02), pages 2695 - 2706
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.